Stryker Corporation $SYK Position Boosted by Davis R M Inc.

Davis R M Inc. boosted its position in Stryker Corporation (NYSE:SYK) by 2.1% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 136,220 shares of the medical technology company’s stock after buying an additional 2,737 shares during the period. Davis R M Inc.’s holdings in Stryker were worth $53,893,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. Nuveen LLC acquired a new stake in shares of Stryker during the 1st quarter valued at approximately $558,075,000. Price T Rowe Associates Inc. MD increased its stake in Stryker by 9.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after purchasing an additional 1,021,496 shares during the last quarter. Alliancebernstein L.P. raised its holdings in shares of Stryker by 66.7% during the first quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company’s stock worth $511,152,000 after purchasing an additional 549,643 shares during the period. Vanguard Group Inc. lifted its position in shares of Stryker by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock worth $12,306,572,000 after buying an additional 361,136 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Stryker by 13.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock worth $838,640,000 after buying an additional 261,058 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of SYK opened at $355.74 on Monday. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19. The stock’s fifty day moving average is $374.63 and its 200-day moving average is $381.38. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The firm has a market capitalization of $136.04 billion, a price-to-earnings ratio of 47.12, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same quarter in the prior year, the firm posted $2.87 EPS. Stryker’s revenue was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 276,173 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the sale, the director owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. The trade was a 9.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Viju Menon sold 500 shares of the stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 520,500 shares of company stock worth $184,803,065 in the last quarter. Company insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

SYK has been the topic of several research reports. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research note on Thursday, September 18th. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. BTIG Research raised their price target on Stryker from $408.00 to $410.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Weiss Ratings downgraded Stryker from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday. Finally, Truist Financial reaffirmed a “hold” rating and issued a $392.00 target price (down from $407.00) on shares of Stryker in a research report on Monday, November 3rd. Thirteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $433.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.